Attached files
file | filename |
---|---|
8-K - FORM 8-K - ACCELLENT INC | d8k.htm |
Exhibit 99.1
Investor Contact: Jeremy Friedman
Executive Vice President and Chief Financial Officer
978 570 6900
Jeremy.friedman@accellent.com
FOR IMMEDIATE RELEASE
Accellent Inc. Announces First Quarter 2011 Results
Wilmington, MA (May 12, 2011) Accellent Inc. (the Company), a wholly owned subsidiary of Accellent Holdings Corp. (Accellent), today announced results for its fiscal first quarter ended March 31, 2011.
First quarter revenue increased 5.9% to $129.9 million and was our fourth consecutive quarter of year over year growth. Revenue growth was experienced across all customer groups, though highlighted by ongoing strength in cardiology. said Donald Spence, President and CEO of Accellent. Driving sustainable revenue growth is paramount to our success as we move forward.
First Quarter 2011 Financial Results
Net sales increased 5.9% to $129.9 million in the first quarter of 2011 compared with $122.7 million in the first quarter of 2010. Income from operations was $13.0 million in the first quarter of 2011, compared to $14.6 million in the first quarter of 2010. Our net loss was $8.2 million in the first quarter of 2011, compared with a net loss of $7.8 million in the first quarter of 2010. The net loss in the first quarter of 2010 included $5.8 million of costs associated with the refinancing of the companys term loan during the quarter.
Adjusted EBITDA for the first quarter of 2011 was $23.8 million, or 18.4% of net sales, compared to Adjusted EBITDA of $24.7 million, or 20.2% of net sales, in the first quarter of 2010.
Reconciliations of non-GAAP financial measures to GAAP financial measures are provided in the financial information accompanying this press release.
Conference Call
Donald Spence, President and Chief Executive Officer, and Jeremy A. Friedman, Executive Vice President and Chief Financial Officer, will discuss our first quarter financial results in a conference call scheduled for today, May 12, 2011 at 5 p.m. Eastern Daylight Time. The teleconference can be accessed live on the Internet through the Investor Relations section of the Accellent website at www.accellent.com or by calling (866) 770-7146 pass code 31513437. Please visit the website or dial in 10 to 15 minutes prior to the beginning of the call to download and install any necessary audio software. A replay of the conference call will be available via www.accellent.com or by telephone at (888) 286-8010 pass code 46650113 until May 19, 2011.
About Accellent
Accellent provides fully integrated outsourced manufacturing and engineering services to the medical device industry primarily in the cardiology, endoscopy and orthopaedic markets. Accellent has broad capabilities in precision component fabrication, finished device assembly, complete supply chain management capabilities and engineering services. These capabilities enhance customers speed to market and return on investment by enabling them to refocus internal resources more efficiently. For more information, please visit www.accellent.com.
Forward-Looking Statements
This press release includes forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended. All statements included herein, other than statements of historical fact, may constitute forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Important factors that could cause actual results to differ materially from the Companys expectations are disclosed in the risk factors contained in the Companys Form 10-K for the year ended December 31, 2010 filed with the Securities and Exchange Commission on March 25, 2011. All forward-looking statements are expressly qualified in their entirety by such risk factors.
ACCELLENT INC.
Unaudited Condensed Consolidated Statements of Operations
For the three months ended March 31, 2011 and 2010
(in thousands)
Three Months Ended | ||||||||
March 31, 2011 |
March 31, 2010 |
|||||||
Net sales |
$ | 129,889 | $ | 122,680 | ||||
Cost of sales (exclusive of amortization) |
98,318 | 90,405 | ||||||
Gross profit |
31,571 | 32,275 | ||||||
Operating expenses: |
||||||||
Selling, general and administrative expenses |
14,112 | 13,251 | ||||||
Research and development expenses |
747 | 679 | ||||||
Amortization of intangible assets |
3,735 | 3,735 | ||||||
Total operating expenses |
18,594 | 17,665 | ||||||
Income from operations |
12,977 | 14,610 | ||||||
Other (expense) income, net: |
||||||||
Interest expense, net |
(17,249 | ) | (17,424 | ) | ||||
Loss on debt extinguishment |
| (5,791 | ) | |||||
Other (expense) income, net |
(1,934 | ) | 2,267 | |||||
Total other (expense) income, net |
(19,183 | ) | (20,948 | ) | ||||
Loss before income taxes |
(6,206 | ) | (6,338 | ) | ||||
Provision for income taxes |
1,965 | 1,481 | ||||||
Net loss |
$ | (8,171 | ) | $ | (7,819 | ) | ||
ACCELLENT INC.
Reconciliation of Net Loss to EBITDA to Adjusted EBITDA
(in thousands)
(unaudited)
Three Months Ended | ||||||||
March 31, 2011 |
March 31, 2010 |
|||||||
Net loss |
$ | (8,171 | ) | $ | (7,819 | ) | ||
Interest expense, net |
17,249 | 17,424 | ||||||
Provision for income taxes |
1,965 | 1,481 | ||||||
Depreciation and amortization |
9,441 | 9,345 | ||||||
EBITDA (1) |
$ | 20,484 | $ | 20,431 | ||||
Stock-based compensation employees |
248 | 16 | ||||||
Stock-based compensation non-employees |
23 | 24 | ||||||
Employee severance and relocation |
335 | 305 | ||||||
Executive recruiting costs |
221 | | ||||||
Plant closure costs |
| 18 | ||||||
Currency transaction loss (gain) |
2,020 | (1,300 | ) | |||||
Change in fair value of derivative instruments |
| (909 | ) | |||||
Other taxes |
190 | 41 | ||||||
Loss on debt extinguishment |
| 5,791 | ||||||
Management fees to stockholder |
319 | 304 | ||||||
Adjusted EBITDA (1) |
$ | 23,840 | $ | 24,721 | ||||
ACCELLENT INC.
Unaudited Condensed Consolidated Balance Sheets
As of March 31, 2011 and December 31, 2010
(in thousands, except share and per share data)
March 31, 2011 |
December 31, 2010 |
|||||||
Assets |
||||||||
Current assets: |
||||||||
Cash |
$ | 30,031 | $ | 40,787 | ||||
Accounts receivable, net |
58,439 | 54,011 | ||||||
Inventory |
75,893 | 66,028 | ||||||
Prepaid expenses and other current assets |
3,829 | 2,650 | ||||||
Total current assets |
168,192 | 163,476 | ||||||
Property, plant and equipment, net |
121,678 | 121,037 | ||||||
Goodwill |
629,854 | 629,854 | ||||||
Intangible assets, net |
160,891 | 164,626 | ||||||
Deferred financing costs and other assets, net |
18,456 | 19,083 | ||||||
Total assets |
$ | 1,099,071 | $ | 1,098,076 | ||||
Liabilities and Stockholders equity |
||||||||
Current liabilities: |
||||||||
Current portion of long-term debt |
$ | 21 | $ | 9 | ||||
Accounts payable |
25,489 | 24,025 | ||||||
Accrued payroll and benefits |
10,979 | 9,102 | ||||||
Accrued interest |
19,514 | 19,787 | ||||||
Accrued expenses and other current liabilities |
18,651 | 17,793 | ||||||
Total current liabilities |
74,654 | 70,716 | ||||||
Long-term debt |
712,747 | 712,675 | ||||||
Other liabilities |
36,681 | 34,177 | ||||||
Total liabilities |
824,082 | 817,568 | ||||||
Stockholders equity |
274,989 | 280,508 | ||||||
Total liabilities and stockholders equity |
$ | 1,099,071 | $ | 1,098,076 | ||||
(1) | EBITDA and Adjusted EBITDA presented in this press release are supplemental measures of our performance that are not required by, or presented in accordance with, GAAP. EBITDA and Adjusted EBITDA are not measurements of our financial performance under GAAP and should not be considered as alternatives to net income (loss) or any other performance measures derived in accordance with GAAP, or as an alternative to cash flow from operating activities as a measure of our liquidity. |
EBITDA represents net income (loss) before net interest expense, provision for income taxes, depreciation and amortization. Adjusted EBITDA represents EBITDA further adjusted to give effect to certain non-cash items and other adjustments, all of which are defined in the indentures governing our debt. The adjustments include adjustments for restructuring charges and related plant closure costs, stock compensation charges, severance and relocation costs, executive recruiting costs, currency transaction gains and losses, gains and losses on derivative instruments, gains and losses resulting from the disposal of property and equipment, certain non-income based taxes, losses on debt extinguishment, and management fees.
We believe that the presentation of EBITDA and Adjusted EBITDA is appropriate to provide additional information to investors. We consider it an important supplemental measure of our performance and we believe that both are frequently used by securities analysts, investors and other interested parties in the evaluation of high yield issuers.